Retraction Note: PI3K/Akt pathway and Nanog maintain cancer stem cells in sarcomas

Affiliations

¹ Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Gastric Surgery, Fujian Medical University Union Hospital, Fujian, China.
³ Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
⁴ Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
⁵ Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. yoons@mskcc.org.

Changhwan Yoon et al. Oncogenesis. 2024.

. 2024 May 29;13(1):18.

doi: 10.1038/s41389-024-00519-0.

¹ Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Gastric Surgery, Fujian Medical University Union Hospital, Fujian, China.
³ Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
⁴ Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
⁵ Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. yoons@mskcc.org.

No abstract available

Retraction of

PI3K/Akt pathway and Nanog maintain cancer stem cells in sarcomas.
Yoon C, Lu J, Yi BC, Chang KK, Simon MC, Ryeom S, Yoon SS. Yoon C, et al. Oncogenesis. 2021 Jan 19;10(1):12. doi: 10.1038/s41389-020-00300-z. Oncogenesis. 2021. Retraction in: Oncogenesis. 2024 May 29;13(1):18. doi: 10.1038/s41389-024-00519-0. PMID: 33468992 Free PMC article. Retracted.

1. Yoon C, Cho SJ, Chang KK, Park DJ, Ryeom SW, Yoon SS. Role of Rac1 pathway in epithelial-to-mesenchymal transition and cancer stem-like cell phenotypes in gastric adenocarcinoma. Mol Cancer Res. 2017;15:1106–16. doi: 10.1158/1541-7786.MCR-17-0053. - DOI - PMC - PubMed
1. Yoon C, Cho SJ, Aksoy BA, Park DJ, Schultz N, Ryeom SW, et al. Chemotherapy resistance in diffuse-type gastric adenocarcinoma is mediated by RhoA activation in cancer stem-like cells. Clin Cancer Res. 2016;22:971–83. doi: 10.1158/1078-0432.CCR-15-1356. - DOI - PMC - PubMed